Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.7K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

4.6K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
4.6K
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

1.3K
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
1.3K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

981
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
981

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Choline alphoscerate: insights between acquired certainties and future perspectives.

Frontiers in aging neuroscience·2026
Same author

Insomnia in seasonal affective disorder: considering the use of benzodiazepines with a focus on lormetazepam.

Frontiers in psychiatry·2026
Same author

Rapid G4 Ligand Screening Through Spectral Changes Using HT-SRCD with Minimal Material.

Molecules (Basel, Switzerland)·2025
Same author

Choline alphoscerate: insights between acquired certainties and future perspectives.

Frontiers in aging neuroscience·2025
Same author

Hypoglycemia and glycemic variability in acute myocardial infarction: the lesser-known aspects of glycemic control.

Cardiovascular diabetology·2025
Same author

Shedding Light on the Antioxidant Activity of Bee Venom Using a 2,2-Diphenyl-1-Picrylhydrazyl Assay in a Detergent-Based Buffer.

Molecules (Basel, Switzerland)·2025

Related Experiment Video

Updated: May 1, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.1K

Differential modulation of GABA(A) receptor function by aryl pyrazoles.

Maria Paola Mascia1, Giovanni Ledda2, Alessandro Orrù3

  • 1CNR - Institute of Neuroscience, Cittadella Universitaria, 09042 Monserrato, Italy.

European Journal of Pharmacology
|April 8, 2014
PubMed
Summary

New aryl pyrazoles show potential as anticonvulsant drugs by modulating GABAA receptors. Their activity depends on molecular structure, binding to specific sites for potential therapeutic effects.

Keywords:
Aryl pyrazolesAryl pyrazoles (PubChem (Ness 0327) CID 10435654)BenzodiazepinesBenzodiazepines (PubChem CID 134664)GABA(A) receptor

More Related Videos

Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors
07:51

Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors

Published on: November 14, 2014

19.5K
Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants
18:01

Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants

Published on: August 18, 2008

13.8K

Related Experiment Videos

Last Updated: May 1, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.1K
Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors
07:51

Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors

Published on: November 14, 2014

19.5K
Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants
18:01

Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants

Published on: August 18, 2008

13.8K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Molecular Biology

Background:

  • GABAA receptors are crucial for neuronal inhibition.
  • Aryl pyrazoles, related to rimonabant, are investigated for their effects on GABAA receptors.
  • Understanding structure-activity relationships is key for developing new therapeutics.

Purpose of the Study:

  • To evaluate the modulatory effects of novel aryl pyrazoles on recombinant GABAA receptors.
  • To determine the influence of molecular structure on the activity of these compounds.
  • To explore the binding sites and mechanisms of action for potential anticonvulsant drug development.

Main Methods:

  • Recombinant human α1β2γ2L GABAA receptors expressed in Xenopus laevis oocytes.
  • Two-electrode voltage-clamp electrophysiology to measure GABA-evoked currents.
  • Assessment of potentiation and antagonism by aryl pyrazoles and reference ligands.

Main Results:

  • 6Bio-R and 14Bio-R potentiated GABA-evoked currents, indicating agonist activity.
  • NESS 0327, GP1a, and GP2a acted as antagonists to 6Bio-R, suggesting allosteric modulation.
  • Flumazenil antagonized 6Bio-R potentiation, implicating the benzodiazepine site; NESS 0327 affected benzodiazepine site ligands but not classical modulators.

Conclusions:

  • Aryl pyrazole activity at GABAA receptors is structure-dependent.
  • Compounds bind to both αβγ and α/β sites, offering potential for subtype-selective modulation.
  • These findings provide structural leads for developing novel anticonvulsant drugs targeting GABAA receptors.